Search

beta-Hydroxybutyric acid

(completed for type 1 diabetes), and NCT05581043 (completed for type 2 diabetes). … Beta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236

Didesmethylrocaglamide

[A186760] While traditionally used for their insecticidal benefits,[A186796] this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_.

Epicept NP-1

Peripheral neuropathies are medical conditions caused by damage to the nerves in the peripheral nervous system. … The peripheral nervous system includes nerves that run from the brain and spinal cord to the rest of the body.

Mitoquinone

Mitochondrial dysfunction also has been shown to represent an early critical event in the pathogenesis of the sporadic form of Parkinson's disease. … -- where they accumulate up to a thousand fold.

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

Chlorfenson

Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.

AVR118

of cancers); for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia … AVR118 is being studied for the promise shown in its ability to mitigate the toxic side effects of other drugs (including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment

Clenbuterol

A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.

LX201

The implant is being developed clinically for the prevention of rejection in corneal transplantation. It is being developed by Lux Biosciences, Inc. … LX201 is a silicone matrix ocular implant that provides sustained release of cyclosporine A (CsA) locally to the eye over the course of one year.

Maxy-G34

It is being developed by Maxygen, Inc. for the treatment of chemotherapy-induced neutropenia. … wild type human G-CSF to avoid PEGylation of such sites.